Company latest

News and press

April 2009

Focus launches Citalopram Drop…

Focus has launched Citalopram Drops, a niche product on the generic market in the UK.…

Full story

Performance and financials

Focus has since 2004 delivered a compound annual growth rate (“CAGR”) in sales and gross profit of 19%. In operating profit, the CAGR was 73%

Focus runs the business under a virtual model, outsourcing any areas that are considered “non-core”. This enables the business to concentrate on areas that add value to the business

The graph below shows the historical and expected growth of the business.